Transcode Therapeutics Inc (RNAZ)

$9.24 +0.82 (9.74%)
Market Cap 7.34M
Revenue (ttm) 0.00
Net Income (ttm) -16.75M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 6,500
Avg Vol 177,430
Day's Range N/A - N/A
Shares Out 834,000.00
Stochastic %K 0%
Beta 1.51
Analysts Strong Buy
Price Target $10.00

Company Profile

TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and t...

Industry: Biotechnology
Sector: Healthcare
Phone: 857-837-3099
Address:
6 Liberty Square, Suite 2382, Boston, United States
d_risk
d_risk Nov. 14 at 9:52 PM
$RNAZ - Transcode Therapeutics, Inc. - 10Q - Updated Risk Factors RNAZ flags past Nasdaq non-compliance, warns of delisting risks and possible shareholder wipeout, highlights urgent need for new capital, and updates on global economic, tax law, and regulatory uncertainties that could disrupt operations and funding. #Biotechnology #DelistingRisk #MarketVolatility #CapitalRaising #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/RNAZ/10-Q/2025-11-14
0 · Reply
ioiioiioiioi
ioiioiioiioi Nov. 12 at 3:41 PM
$RNAZ 🤯
0 · Reply
Hovius
Hovius Nov. 7 at 4:50 PM
$RNAZ I was hoping couple of months… not couple days.. Damn..
1 · Reply
Love_To_Learn
Love_To_Learn Nov. 7 at 1:13 PM
$RNAZ need u shortly
0 · Reply
Vedran1
Vedran1 Nov. 6 at 8:01 PM
$RNAZ 3Mon:Day chart smooths out some of the noise as opposed to 3Mon:4h chart as in my previous post.
0 · Reply
Vedran1
Vedran1 Nov. 6 at 7:43 PM
$RNAZ Added 20 shares at 9.60 this am by using my biweekly $200 allotment toward RNAZ. Ideally, one would buy after RNAZ downfall steadies or goes up some for a few days to weeks. "Selling volumes" are not big at all but there is consistent selling looking at Stock price, RSI, MACD and On Balance Volume chart. RSI is low at the time. Low RSI, low selling volumes and positive own sentiment made me to add today. Here is 3-month chart:
0 · Reply
Hovius
Hovius Nov. 6 at 4:52 PM
$RNAZ Sadly, this will not recover when everything else does. Good luck everyone
0 · Reply
phantomtrader75
phantomtrader75 Nov. 6 at 12:28 AM
$RNAZ a big 30% pop is coming.
1 · Reply
TradeHuntFish
TradeHuntFish Nov. 4 at 3:49 PM
VEEE is constructing an ideal setup: • Bottoming price action and technicals hint at a base formation. (see TradingView for chart compression)  • News flow accelerating with real tech pivot announcements. • Short interest as a percentage of float is elevated enough to trigger squeeze sentiment.  One breakout candle with volume could open a wide upside gap. $UDMY $RCAT $ACHL $RNAZ
2 · Reply
ioiioiioiioi
ioiioiioiioi Nov. 4 at 3:29 PM
$RNAZ What do you all think — will there be a rebound when Phase 2 starts? It seems like patient enrollment is already complete, so maybe early next year (Q1 2026) we’ll finally see it happen. 😭
2 · Reply
Latest News on RNAZ
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO

Oct 14, 2025, 8:06 AM EDT - 4 weeks ago

TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO

TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board

May 28, 2025, 8:00 AM EDT - 6 months ago

TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

May 8, 2025, 8:05 AM EDT - 6 months ago

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

May 5, 2025, 5:07 PM EDT - 6 months ago

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

May 2, 2025, 4:10 PM EDT - 7 months ago

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

May 1, 2025, 9:01 AM EDT - 7 months ago

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

Apr 21, 2025, 4:37 PM EDT - 7 months ago

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

Mar 27, 2025, 4:37 PM EDT - 8 months ago

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

Mar 25, 2025, 6:24 PM EDT - 8 months ago

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mar 23, 2025, 11:11 PM EDT - 8 months ago

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

Mar 13, 2025, 7:47 AM EDT - 8 months ago

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

TransCode Therapeutics, Inc. Announces Results of Special Meeting

Feb 25, 2025, 4:15 PM EST - 9 months ago

TransCode Therapeutics, Inc. Announces Results of Special Meeting

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

Feb 6, 2025, 8:00 AM EST - 10 months ago

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

Jan 14, 2025, 8:00 AM EST - 10 months ago

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

Jan 7, 2025, 8:00 AM EST - 11 months ago

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

Dec 18, 2024, 8:00 AM EST - 11 months ago

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

Nov 29, 2024, 4:25 PM EST - 1 year ago

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

TransCode Therapeutics, Inc. Announces $8 Million Private Placement

Nov 27, 2024, 7:00 AM EST - 1 year ago

TransCode Therapeutics, Inc. Announces $8 Million Private Placement

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

Nov 5, 2024, 7:00 AM EST - 1 year ago

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

Sep 17, 2024, 7:00 AM EDT - 1 year ago

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate

Sep 5, 2024, 7:00 AM EDT - 1 year ago

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate

TransCode Therapeutics, Inc. Announces Closing of Public Offering

Jul 24, 2024, 4:05 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Closing of Public Offering

TransCode Therapeutics, Inc. Announces Pricing of Public Offering

Jul 22, 2024, 10:30 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Pricing of Public Offering

TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Jul 22, 2024, 4:07 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

May 29, 2024, 9:15 AM EDT - 1 year ago

TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

TransCode Therapeutics Open Letter to Shareholders

May 13, 2024, 8:30 AM EDT - 1 year ago

TransCode Therapeutics Open Letter to Shareholders

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors

Apr 15, 2024, 9:00 AM EDT - 1 year ago

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors

TransCode Therapeutics Reports 2023 Results; Provides Business Update

Apr 3, 2024, 9:10 AM EDT - 1 year ago

TransCode Therapeutics Reports 2023 Results; Provides Business Update

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

Mar 28, 2024, 8:30 AM EDT - 1 year ago

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment

Mar 11, 2024, 9:00 AM EDT - 1 year ago

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment

TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress

Mar 6, 2024, 4:15 PM EST - 1 year ago

TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist Immunotherapeutic

Feb 20, 2024, 8:00 AM EST - 1 year ago

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist Immunotherapeutic

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock Market

Jan 31, 2024, 4:05 PM EST - 1 year ago

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock Market

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

Jan 29, 2024, 8:30 AM EST - 1 year ago

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

TransCode Therapeutics Announces Closing of $7.25 Million Public Offering

Jan 22, 2024, 4:45 PM EST - 1 year ago

TransCode Therapeutics Announces Closing of $7.25 Million Public Offering

TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering

Jan 18, 2024, 1:27 PM EST - 1 year ago

TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering

TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO

Jan 12, 2024, 4:05 PM EST - 2 years ago

TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

Jan 11, 2024, 8:00 AM EST - 2 years ago

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

TransCode Therapeutics Publishes Open Letter Outlining Company's Progress and Objectives

Jan 4, 2024, 8:05 AM EST - 2 years ago

TransCode Therapeutics Publishes Open Letter Outlining Company's Progress and Objectives

TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138

Dec 12, 2023, 8:30 AM EST - 2 years ago

TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138

TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium

Dec 5, 2023, 9:00 AM EST - 2 years ago

TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium

TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

Dec 4, 2023, 4:10 PM EST - 2 years ago

TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

Nov 30, 2023, 2:53 PM EST - 2 years ago

TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update

Nov 14, 2023, 4:30 PM EST - 2 years ago

TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update

TransCode Therapeutics Withdraws Public Offering

Oct 30, 2023, 4:33 PM EDT - 2 years ago

TransCode Therapeutics Withdraws Public Offering

Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions

Oct 27, 2023, 8:00 AM EDT - 2 years ago

Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions

TransCode Therapeutics Announces Public Offering of Common Stock

Oct 26, 2023, 4:19 PM EDT - 2 years ago

TransCode Therapeutics Announces Public Offering of Common Stock

TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138

Oct 26, 2023, 8:00 AM EDT - 2 years ago

TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138

TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138

Oct 24, 2023, 8:00 AM EDT - 2 years ago

TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138

TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA

Oct 16, 2023, 8:00 AM EDT - 2 years ago

TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA

d_risk
d_risk Nov. 14 at 9:52 PM
$RNAZ - Transcode Therapeutics, Inc. - 10Q - Updated Risk Factors RNAZ flags past Nasdaq non-compliance, warns of delisting risks and possible shareholder wipeout, highlights urgent need for new capital, and updates on global economic, tax law, and regulatory uncertainties that could disrupt operations and funding. #Biotechnology #DelistingRisk #MarketVolatility #CapitalRaising #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/RNAZ/10-Q/2025-11-14
0 · Reply
ioiioiioiioi
ioiioiioiioi Nov. 12 at 3:41 PM
$RNAZ 🤯
0 · Reply
Hovius
Hovius Nov. 7 at 4:50 PM
$RNAZ I was hoping couple of months… not couple days.. Damn..
1 · Reply
Love_To_Learn
Love_To_Learn Nov. 7 at 1:13 PM
$RNAZ need u shortly
0 · Reply
Vedran1
Vedran1 Nov. 6 at 8:01 PM
$RNAZ 3Mon:Day chart smooths out some of the noise as opposed to 3Mon:4h chart as in my previous post.
0 · Reply
Vedran1
Vedran1 Nov. 6 at 7:43 PM
$RNAZ Added 20 shares at 9.60 this am by using my biweekly $200 allotment toward RNAZ. Ideally, one would buy after RNAZ downfall steadies or goes up some for a few days to weeks. "Selling volumes" are not big at all but there is consistent selling looking at Stock price, RSI, MACD and On Balance Volume chart. RSI is low at the time. Low RSI, low selling volumes and positive own sentiment made me to add today. Here is 3-month chart:
0 · Reply
Hovius
Hovius Nov. 6 at 4:52 PM
$RNAZ Sadly, this will not recover when everything else does. Good luck everyone
0 · Reply
phantomtrader75
phantomtrader75 Nov. 6 at 12:28 AM
$RNAZ a big 30% pop is coming.
1 · Reply
TradeHuntFish
TradeHuntFish Nov. 4 at 3:49 PM
VEEE is constructing an ideal setup: • Bottoming price action and technicals hint at a base formation. (see TradingView for chart compression)  • News flow accelerating with real tech pivot announcements. • Short interest as a percentage of float is elevated enough to trigger squeeze sentiment.  One breakout candle with volume could open a wide upside gap. $UDMY $RCAT $ACHL $RNAZ
2 · Reply
ioiioiioiioi
ioiioiioiioi Nov. 4 at 3:29 PM
$RNAZ What do you all think — will there be a rebound when Phase 2 starts? It seems like patient enrollment is already complete, so maybe early next year (Q1 2026) we’ll finally see it happen. 😭
2 · Reply
TradeHuntFish
TradeHuntFish Nov. 4 at 4:15 AM
VEEE is constructing an ideal setup: • Bottoming price action and technicals hint at a base formation. (see TradingView for chart compression)  • News flow accelerating with real tech pivot announcements. • Short interest as a percentage of float is elevated enough to trigger squeeze sentiment.  One breakout candle with volume could open a wide upside gap. $UDMY $RCAT $ACHL $RNAZ
0 · Reply
Hovius
Hovius Nov. 3 at 9:30 PM
$RNAZ Another brutal day…. Sure seems to be going back to $10 and then $8 and then $6.
3 · Reply
Vedran1
Vedran1 Oct. 31 at 7:58 PM
$RNAZ me: Based on recent TransCode Therapeutics SEC filings, what is a conversion price of series A and B convertible shares? Gemini: Conversion Price = $11.17 per share See detailed Gemini's answer here: https://g.co/gemini/share/532d8f5eab76
2 · Reply
Vondde
Vondde Oct. 31 at 2:58 PM
$RNAZ Assuming TTX-MC138 gets FDA approval, does anyone have an educated estimate of what RNAZ's market cap will be after FDA approval?
4 · Reply
ChaseDeluca
ChaseDeluca Oct. 31 at 12:57 PM
QCLS has all the marks: rebrand, tech upgrade, minimal public float. When quantum compute meets crypto infrastructure and volume shows up – that’s when things get dirty. You want in before the move. $BIAF $CHNR $RNAZ $MBRX
0 · Reply
Hovius
Hovius Oct. 30 at 8:28 PM
$RNAZ Now we have Cayman Islands buying RNAz stock… That’s shift as fugh. https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=319533461&type=PDF&symbol=RNAZ&cdn=054b1aec25d9ee5f39912c476e756071&companyName=TransCode+Therapeutics+Inc.&formType=SCHEDULE+13D%2FA&dateFiled=2025-10-28
0 · Reply
Vedran1
Vedran1 Oct. 30 at 6:38 PM
$RNAZ So it feels to me like we got sold for a potential and deferred reward, instead of up front cash distribution to shareholders. The result is lesser risk and lesser cost to our buyer - a majority shareholder. And in return original shareholders got rewarded with a potential to get something anywhere from nothing to something over next 7 years. It is a good and safer deal for buyer. I feel, for RNAZ to turn around post Oct 20, we need some really good news attracting new investors.
2 · Reply
phantomtrader75
phantomtrader75 Oct. 30 at 5:52 PM
$RNAZ POS 💩
0 · Reply
Hovius
Hovius Oct. 30 at 5:08 PM
$RNAZ Wow Another brutal day
0 · Reply
BillionerOfKing
BillionerOfKing Oct. 30 at 1:33 PM
$RNAZ Current Stock Price: $12.00 No options data available.
0 · Reply
ioiioiioiioi
ioiioiioiioi Oct. 30 at 1:23 PM
$RNAZ Is this right…?😱🤯
1 · Reply
Hovius
Hovius Oct. 29 at 9:43 PM
$RNAZ Back to crap… oh well
1 · Reply